Short answer
Idexx Laboratories (IDXX) filed an 8-K current report with the SEC on August 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results announced August 4, 2026.
Idexx Laboratories 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results announced August 4, 2026
- Press release contains the substantive financial results and management disclosures
- Investors should review Exhibit 99.1 for revenue, earnings, guidance, and operating performance details
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $1,217M, up 10% reported and 9% organic, led by CAG Diagnostics recurring revenue growth of 11% reported
- EPS $4.27, up 18% reported and 15% comparable, with operating margin expanding 140 basis points to 35.0%
- IDEXX inVue Dx installed base surpassed 9,000 instruments after over 1,600 quarterly placements, supporting future recurring consumables revenue
- 2026 revenue guidance narrowed to $4,700M-$4,745M, with midpoint increased $5M despite a $15M foreign-exchange headwind
- 2026 EPS outlook raised to $14.69-$14.94, up $0.14 at midpoint, while operating-margin guidance increased to 32.3%-32.5%
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Idexx Laboratories 8-K filings
Get the next IDXX 8-K as it lands
Follow IDXX for push alerts, or ask the research agent what this filing means.